1. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E6(R2).GuidelineforGoodClinicalPractices.2016https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.Accessedon24-OCT-2023.
2. International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. E8(R1).GuidelineonGeneralConsiderationsforClinicalStudies.2021.https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-e8-r1-general-considerations-clinical-studies_en.pdf.Accessed24-OCT-2023
3. Food and Drug Administration.GuidanceforIndustry:InvestigatorResponsibilities—ProtectingtheRights,Safety,andWelfareofStudySubjects.2009.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM187772.pdf.Accessed24-OCT-2023
4. Follow-up on the Use of Advanced Analytics for Clinical Quality Assurance: Bootstrap Resampling to Enhance Detection of Adverse Event Under-Reporting;Koneswarakantha B;Drug Saf,2021
5. KoneswarakanthaB.SIMAERP-Open-sourcePackageforClinicalSafetyreporting.Coderepository.https://github.com/openpharma/simaerep.Accessedon24-OCT-2023